A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Nov 19, 2014

The results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol including new sub-group Analyses focusing on baseline patient characteristics were Announced at 2014 meeting of leading rheumatology meeting

The additional sub-group analyses of C-OPERA in findings regarding the inhibition of joint structural destruction were reported at the American College of Rheumatology/Association of Rheumatology...

Read more about The results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol including new sub-group Analyses focusing on baseline patient characteristics were Announced at 2014 meeting of leading rheumatology meeting
Nov 4, 2014

Changing Tomorrow Day 2014 Marks Astellas' Fifth Annual Global Service Initiative -More than 6,000 employees worldwide have already completed over 13,000 hours of volunteer service in their communities-

Tokyo, Japan - Nov. 4, 2014 – Astellas Pharma Inc. (Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced for the fifth consecutive year, Astellas Group’s global volunteer...

Read more about Changing Tomorrow Day 2014 Marks Astellas' Fifth Annual Global Service Initiative -More than 6,000 employees worldwide have already completed over 13,000 hours of volunteer service in their communities-
Nov 4, 2014

DANA-FARBER CANCER INSTITUTE AND ASTELLAS ANNOUNCE - Focus on research and development for small molecule inhibitors of oncogenic K-Ras- the most commonly mutated oncogene in human cancers -

BOSTON and TOKYO, JAPAN – Nov. 4th, 2014 – Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. (Tokyo: 4503) today announced a three-year collaboration to research and develop...

Read more about DANA-FARBER CANCER INSTITUTE AND ASTELLAS ANNOUNCE - Focus on research and development for small molecule inhibitors of oncogenic K-Ras- the most commonly mutated oncogene in human cancers -
Nov 4, 2014

Proteostasis Therapeutics and Astellas Announce Collaboration for Research, Development and Commercialization of Therapies Modulating the Unfolded Protein Response

Cambridge, Mass. and Tokyo, Japan, November 4th, 2014 -- Proteostasis Therapeutics, Inc. (“Proteostasis Therapeutics”), a company developing novel therapeutics to address diseases caused by...

Read more about Proteostasis Therapeutics and Astellas Announce Collaboration for Research, Development and Commercialization of Therapies Modulating the Unfolded Protein Response
Oct 31, 2014

Astellas Announces Revision of Dividend Forecast (Increase Dividends) for FY2014 ending March 31, 2015

Read more about Astellas Announces Revision of Dividend Forecast (Increase Dividends) for FY2014 ending March 31, 2015

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts